{"disease":{"id":"braf-v600-mutated-stage-iii-iv-melanoma","name":"braf v600 mutated stage iii iv melanoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06557291","title":"Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma","phase":"","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Novartis","has_results":false},{"nct_id":"NCT06784648","title":"Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"BioInvent International AB","has_results":false},{"nct_id":"NCT01826448","title":"A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Daiichi Sankyo","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}